Caplin Point Laboratories share news and announcements
NSE: CAPLIPOINTBSE: 524742Pharmaceuticals & BiotechnologySmall Cap
Last close ₹2,222.00down ₹27.10 (1.20%)BSE ₹2,222.15
Share price at the NSE close on 23 Oct 2026. Previous close ₹2,249.10.
52-week range of traded prices to 23 Oct 2026
₹1,500.30Low, 30 Mar 2026₹2,990.00High, 24 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹16,890 Cr453rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 12 Aug 2026
- 25.4
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 14 May 2026
- 4.7
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.36%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 12 Aug 2026
- 20.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 12 Aug 2026
- 19.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 14 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 76,90447.0% delivered
Caplin Point Laboratories record dates, bonuses and splits
20 filed, newest first.
Aug 2026
12 Aug · Corporate action
Aug 2025
7 Aug · Corporate action
May 2025
15 May · Corporate action
Aug 2024
7 Aug · Corporate action
May 2024
30 May · Corporate action
Aug 2023
May 2023
27 May · Corporate action
Sep 2022
5 Sep · Corporate action
May 2022
17 May · Corporate action
Sep 2021
May 2021
8 May · Corporate action
Sep 2020
Feb 2020
Sep 2018
Oct 2016
Aug 2016
5 Aug · Corporate action
Board of Directors of the Company at their Meeting held on August 05, 2016, have approved the Sub-division of existing Equity Shares of Face Value of Rs.10/- each into(5) Five Equity Shares of face value of Rs.2/- each, subject to the approval of Members of the Company at the ensuing Annual General Meeting and Regulatory/ Statutory Approvals
Jan 2016